Type 2 Diabetes – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Type 2 Diabetes – Pipeline Review, H2 2016’, provides an overview of the Type 2 Diabetes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes

The report reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Type 2 Diabetes therapeutics and enlists all their major and minor projects

The report assesses Type 2 Diabetes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Type 2 Diabetes

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Adocia

Advinus Therapeutics Ltd

Aegis Therapeutics, LLC

AFFiRiS AG

Alize Pharma SAS

AlphaMab Co., Ltd

Alteogen Inc.

Amarantus Bioscience Holdings, Inc.

Ambrx, Inc.

Amgen Inc.

Anchor Therapeutics, Inc.

AntriaBio, Inc.

Aphios Corporation

APT Therapeutics, Inc.

Araim Pharmaceuticals, Inc.

Arisaph Pharmaceuticals, Inc.

ArisGen SA

Artery Therapeutics, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Aus Bio Ltd

Bayer AG

Beta-Cell NV

Betagenon AB

Biocon Limited

Biodel Inc.

Biogenomics Limited

BioLingus AG

BioRestorative Therapies, Inc.

BioTherapeutics Inc.

Biscayne Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Boston Therapeutics, Inc.

Braasch Biotech LLC

Bristol-Myers Squibb Company

C4X Discovery Holdings PLC

Cadila Pharmaceuticals Limited

Caldan Therapeutics Limited

Cardax, Inc.

Carlina Technologies SAS

Carmot Therapeutics Inc

Celon Pharma Sp. z o.o.

Chipscreen Biosciences Ltd

Chong Kun Dang Pharmaceutical Corp.

CJ HealthCare Corp.

CohBar, Inc.

ConjuChem, LLC

Connexios Life Sciences Pvt. Ltd.

Corium International, Inc.

CureDM, Inc.

CymaBay Therapeutics, Inc.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Dance Biopharm Inc.

Delpor, Inc.

Diabetica Limited

Diabetology (Products) Ltd

DiaMedica Inc.

Diamyd Medical AB

Diasome Pharmaceuticals, Inc.

DiscoveryBiomed, Inc.

DNJ Pharma, Inc.

Dong-A Socio Holdings Co. Ltd.

Elcelyx Therapeutics Inc

Eli Lilly and Company

enGene, Inc

Enzo Biochem, Inc.

Epichem Pty Ltd

Esperion Therapeutics, Inc.

Eternygen GmbH

Evotec AG

F. Hoffmann-La Roche Ltd.

FibroStatin SL

Flamel Technologies S.A.

Generex Biotechnology Corporation

Genfit SA

Genovate Biotechnology Co., LTD.

Gero Corp

Geropharm

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Glide Pharmaceutical Technologies Limited

Glucox Biotech AB

GW Pharmaceuticals Plc

Hadasit Medical Research Services & Development Ltd

HanAll Biopharma Co., Ltd.

Handok Inc.

Hanmi Pharmaceuticals, Co. Ltd.

HEC Pharm Co., Ltd.

Heptares Therapeutics Limited

HitGen LTD

Hua Medicine (Shanghai) Ltd.

Hyundai Pharmaceutical Co., Ltd.

Immuron Limited

Innopharmax Inc.

Innovative Targeting Solutions Inc

Intarcia Therapeutics, Inc.

Intas Pharmaceuticals Ltd.

Integral Molecular, Inc.

Intercept Pharmaceuticals, Inc.

Intrexon Corporation

Ionis Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.

Islet Sciences, Inc.

Ixchel Pharma, LLC

Japan Tobacco Inc.

Jeil Pharmaceutical Co., Ltd.

Jenrin Discovery, Inc.

JHL Biotech, Inc.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Johnson & Johnson

Kadimastem Ltd.

Kadmon Corporation, LLC

Kareus Therapeutics, SA

Kissei Pharmaceutical Co., Ltd.

Lead Discovery Center GmbH

Leading BioSciences, Inc.

Lexicon Pharmaceuticals, Inc.

LG Life Science LTD.

Ligand Pharmaceuticals, Inc.

LipimetiX Development Inc

Lonestar Heart, Inc.

Longevity Biotech, Inc

Magnus Life Ltd

Medesis Pharma S.A.

Medestea Research & Production S.p.A.

MedImmune LLC

Mellitech SAS

Merck & Co., Inc.

Mesoblast Limited

Metabolic Solutions Development Company, LLC

Metabolys SAS

Metacrine, Inc.

MicroBiome Therapeutics LLC

MidaSol Therapeutics LP

Mitsubishi Tanabe Pharma Corporation

Moderna Therapeutics Inc

Naia Limited

Neurimmune Holding AG

Neurocrine Biosciences, Inc.

NGM Biopharmaceuticals, Inc.

Nordic Bioscience A/S

Novapeutics, LLC

Novartis AG

NovaTarg Therapeutics, Inc

Novo Nordisk A/S

Noxxon Pharma AG

Ogeda SA

Omeros Corporation

OPKO Biologics Ltd

OPKO Health, Inc.

Oramed Pharmaceuticals, Inc.

Orbis Biosciences Inc

Panacea Biotec Limited

Paras Biopharmaceuticals Finland Oy

Peptron, Inc.

Pfizer Inc.

PharmaCyte Biotech, Inc.

PharmaIN Corporation

PhaseBio Pharmaceuticals, Inc.

Pila Pharma AB

Pivot Pharmaceuticals Inc

Poxel SA

Prometheon Pharma, LLC

ProMetic Life Sciences Inc.

Purzer Pharmaceutical Co., Ltd.

Reata Pharmaceuticals, Inc.

ReCyte Therapeutics, Inc.

Red Glead Discovery AB

RegenMedTX, LLC

reMYND NV

Renova Therapeutics Inc

Saniona AB

Sanofi

Sanwa Kagaku Kenkyusho Co., Ltd.

SATT Conectus Alsace SAS

SBI Pharmaceuticals Co., Ltd.

Selvita S.A.

Seres Therapeutics, Inc.

Serodus ASA

Serometrix, LLC

Sevion Therapeutics, Inc.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shantani Proteome Analytics Pvt. Ltd.

Shionogi & Co., Ltd.

Sihuan Pharmaceutical Holdings Group Ltd.

Sirona Biochem Corp

SJT Molecular Research, S.L.

SK Chemicals Co., Ltd.

Sprint Bioscience AB

Starpharma Holdings Limited

Stelic Institute & Co., Inc.

Strongbridge Biopharma plc

Sumitomo Dainippon Pharma Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Takeda Pharmaceutical Company Limited

Teijin Pharma Limited

Theracos, Inc.

Therapix Biosciences Ltd.

Thermalin Diabetes, LLC

Thetis Pharmaceuticals LLC

Toray Industries, Inc.

Torrent Pharmaceuticals Limited

Transgene Biotek Limited

TWi Pharmaceuticals, Inc.

Uni-Bio Science Group Ltd.

Valeant Pharmaceuticals International, Inc.

Venenum Biodesign, L.L.C

ViaCyte, Inc.

Vichem Chemie Research Ltd.

Vicore Pharma AB

Viking Therapeutics, Inc.

Virobay Inc.

Vivus, Inc.

vTv Therapeutics Inc

Vybion, Inc.

XBiotech Inc

Xenetic Biosciences (UK) Limited

Xizang Haisco Pharmaceutical Group Co., Ltd.

XL-protein GmbH

XOMA Corporation

XuanZhu Pharma Co Ltd

Yuhan Corporation

Yungjin Pharm. Co., Ltd.

Zealand Pharma A/S

Zensun (Shanghai) Sci & Tech Co., Ltd.

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

Introduction 12

Type 2 Diabetes Overview 13

Therapeutics Development 14

Type 2 Diabetes - Therapeutics under Development by Companies 16

Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes 36

Type 2 Diabetes - Pipeline Products Glance 40

Type 2 Diabetes - Products under Development by Companies 44

Type 2 Diabetes - Products under Investigation by Universities/Institutes 78

Type 2 Diabetes - Companies Involved in Therapeutics Development 84

Type 2 Diabetes - Therapeutics Assessment 313

Drug Profiles 368

Type 2 Diabetes - Dormant Projects 1156

Type 2 Diabetes - Discontinued Products 1204

Type 2 Diabetes - Product Development Milestones 1223

Appendix 1236

List of Tables

List of Tables

Number of Products under Development for Type 2 Diabetes, H2 2016 75

Number of Products under Development for Type 2 Diabetes – Comparative Analysis, H2 2016 76

Number of Products under Development by Companies, H2 2016 78

Number of Products under Development by Companies, H2 2016 (Contd..1) 79

Number of Products under Development by Companies, H2 2016 (Contd..2) 80

Number of Products under Development by Companies, H2 2016 (Contd..3) 81

Number of Products under Development by Companies, H2 2016 (Contd..4) 82

Number of Products under Development by Companies, H2 2016 (Contd..5) 83

Number of Products under Development by Companies, H2 2016 (Contd..6) 84

Number of Products under Development by Companies, H2 2016 (Contd..7) 85

Number of Products under Development by Companies, H2 2016 (Contd..8) 86

Number of Products under Development by Companies, H2 2016 (Contd..9) 87

Number of Products under Development by Companies, H2 2016 (Contd..10) 88

Number of Products under Development by Companies, H2 2016 (Contd..11) 89

Number of Products under Development by Companies, H2 2016 (Contd..12) 90

Number of Products under Development by Companies, H2 2016 (Contd..13) 91

Number of Products under Development by Companies, H2 2016 (Contd..14) 92

Number of Products under Development by Companies, H2 2016 (Contd..15) 93

Number of Products under Development by Companies, H2 2016 (Contd..16) 94

Number of Products under Development by Companies, H2 2016 (Contd..17) 95

Number of Products under Development by Companies, H2 2016 (Contd..18) 96

Number of Products under Investigation by Universities/Institutes, H2 2016 97

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 98

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 99

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 100

Comparative Analysis by Late Stage Development, H2 2016 101

Comparative Analysis by Clinical Stage Development, H2 2016 102

Comparative Analysis by Early Stage Development, H2 2016 103

Comparative Analysis by Unknown Stage Development, H2 2016 104

Products under Development by Companies, H2 2016 105

Products under Development by Companies, H2 2016 (Contd..1) 106

Products under Development by Companies, H2 2016 (Contd..2) 107

Products under Development by Companies, H2 2016 (Contd..3) 108

Products under Development by Companies, H2 2016 (Contd..4) 109

Products under Development by Companies, H2 2016 (Contd..5) 110

Products under Development by Companies, H2 2016 (Contd..6) 111

Products under Development by Companies, H2 2016 (Contd..7) 112

Products under Development by Companies, H2 2016 (Contd..8) 113

Products under Development by Companies, H2 2016 (Contd..9) 114

Products under Development by Companies, H2 2016 (Contd..10) 115

Products under Development by Companies, H2 2016 (Contd..11) 116

Products under Development by Companies, H2 2016 (Contd..12) 117

Products under Development by Companies, H2 2016 (Contd..13) 118

Products under Development by Companies, H2 2016 (Contd..14) 119

Products under Development by Companies, H2 2016 (Contd..15) 120

Products under Development by Companies, H2 2016 (Contd..16) 121

Products under Development by Companies, H2 2016 (Contd..17) 122

Products under Development by Companies, H2 2016 (Contd..18) 123

Products under Development by Companies, H2 2016 (Contd..19) 124

Products under Development by Companies, H2 2016 (Contd..20) 125

Products under Development by Companies, H2 2016 (Contd..21) 126

Products under Development by Companies, H2 2016 (Contd..22) 127

Products under Development by Companies, H2 2016 (Contd..23) 128

Products under Development by Companies, H2 2016 (Contd..24) 129

Products under Development by Companies, H2 2016 (Contd..25) 130

Products under Development by Companies, H2 2016 (Contd..26) 131

Products under Development by Companies, H2 2016 (Contd..27) 132

Products under Development by Companies, H2 2016 (Contd..28) 133

Products under Development by Companies, H2 2016 (Contd..29) 134

Products under Development by Companies, H2 2016 (Contd..30) 135

Products under Development by Companies, H2 2016 (Contd..31) 136

Products under Development by Companies, H2 2016 (Contd..32) 137

Products under Development by Companies, H2 2016 (Contd..33) 138

Products under Investigation by Universities/Institutes, H2 2016 139

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 140

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 141

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 142

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 143

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 144

Type 2 Diabetes – Pipeline by Addex Therapeutics Ltd, H2 2016 145

Type 2 Diabetes – Pipeline by Adocia, H2 2016 146

Type 2 Diabetes – Pipeline by Advinus Therapeutics Ltd, H2 2016 147

Type 2 Diabetes – Pipeline by Aegis Therapeutics, LLC, H2 2016 148

Type 2 Diabetes – Pipeline by AFFiRiS AG, H2 2016 149

Type 2 Diabetes – Pipeline by Alize Pharma SAS, H2 2016 150

Type 2 Diabetes – Pipeline by AlphaMab Co., Ltd, H2 2016 151

Type 2 Diabetes – Pipeline by Alteogen Inc., H2 2016 152

Type 2 Diabetes – Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 153

Type 2 Diabetes – Pipeline by Ambrx, Inc., H2 2016 154

Type 2 Diabetes – Pipeline by Amgen Inc., H2 2016 155

Type 2 Diabetes – Pipeline by Anchor Therapeutics, Inc., H2 2016 156

Type 2 Diabetes – Pipeline by AntriaBio, Inc., H2 2016 157

Type 2 Diabetes – Pipeline by Aphios Corporation, H2 2016 158

Type 2 Diabetes – Pipeline by APT Therapeutics, Inc., H2 2016 159

Type 2 Diabetes – Pipeline by Araim Pharmaceuticals, Inc., H2 2016 160

Type 2 Diabetes – Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 161

Type 2 Diabetes – Pipeline by ArisGen SA, H2 2016 162

Type 2 Diabetes – Pipeline by Artery Therapeutics, Inc., H2 2016 163

Type 2 Diabetes – Pipeline by Astellas Pharma Inc., H2 2016 164

Type 2 Diabetes – Pipeline by AstraZeneca Plc, H2 2016 165

Type 2 Diabetes – Pipeline by Aus Bio Ltd, H2 2016 166

Type 2 Diabetes – Pipeline by Bayer AG, H2 2016 167

Type 2 Diabetes – Pipeline by Beta-Cell NV, H2 2016 168

Type 2 Diabetes – Pipeline by Betagenon AB, H2 2016 169

Type 2 Diabetes – Pipeline by Biocon Limited, H2 2016 170

Type 2 Diabetes – Pipeline by Biodel Inc., H2 2016 171

Type 2 Diabetes – Pipeline by Biogenomics Limited, H2 2016 172

Type 2 Diabetes – Pipeline by BioLingus AG, H2 2016 173

Type 2 Diabetes – Pipeline by BioRestorative Therapies, Inc., H2 2016 174

Type 2 Diabetes – Pipeline by BioTherapeutics Inc., H2 2016 175

Type 2 Diabetes – Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016 176

Type 2 Diabetes – Pipeline by Boehringer Ingelheim GmbH, H2 2016 177

Type 2 Diabetes – Pipeline by Boston Therapeutics, Inc., H2 2016 178

Type 2 Diabetes – Pipeline by Braasch Biotech LLC, H2 2016 179

Type 2 Diabetes – Pipeline by Bristol-Myers Squibb Company, H2 2016 180

Type 2 Diabetes – Pipeline by C4X Discovery Holdings PLC, H2 2016 181

Type 2 Diabetes – Pipeline by Cadila Pharmaceuticals Limited, H2 2016 182

Type 2 Diabetes – Pipeline by Caldan Therapeutics Limited, H2 2016 183

Type 2 Diabetes – Pipeline by Cardax, Inc., H2 2016 184

Type 2 Diabetes – Pipeline by Carlina Technologies SAS, H2 2016 185

Type 2 Diabetes – Pipeline by Carmot Therapeutics Inc, H2 2016 186

Type 2 Diabetes – Pipeline by Celon Pharma Sp. z o.o., H2 2016 187

Type 2 Diabetes – Pipeline by Chipscreen Biosciences Ltd, H2 2016 188

Type 2 Diabetes – Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 189

Type 2 Diabetes – Pipeline by CJ HealthCare Corp., H2 2016 190

Type 2 Diabetes – Pipeline by CohBar, Inc., H2 2016 191

Type 2 Diabetes – Pipeline by ConjuChem, LLC, H2 2016 192

Type 2 Diabetes – Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 193

Type 2 Diabetes – Pipeline by Corium International, Inc., H2 2016 194

Type 2 Diabetes – Pipeline by CureDM, Inc., H2 2016 195

Type 2 Diabetes – Pipeline by CymaBay Therapeutics, Inc., H2 2016 196

Type 2 Diabetes – Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 197

Type 2 Diabetes – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 198

Type 2 Diabetes – Pipeline by Dance Biopharm Inc., H2 2016 199

Type 2 Diabetes – Pipeline by Delpor, Inc., H2 2016 200

Type 2 Diabetes – Pipeline by Diabetica Limited, H2 2016 201

Type 2 Diabetes – Pipeline by Diabetology (Products) Ltd, H2 2016 202

Type 2 Diabetes – Pipeline by DiaMedica Inc., H2 2016 203

Type 2 Diabetes – Pipeline by Diamyd Medical AB, H2 2016 204

Type 2 Diabetes – Pipeline by Diasome Pharmaceuticals, Inc., H2 2016 205

Type 2 Diabetes – Pipeline by DiscoveryBiomed, Inc., H2 2016 206

Type 2 Diabetes – Pipeline by DNJ Pharma, Inc., H2 2016 207

Type 2 Diabetes – Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 208

Type 2 Diabetes – Pipeline by Elcelyx Therapeutics Inc, H2 2016 209

Type 2 Diabetes – Pipeline by Eli Lilly and Company, H2 2016 210

Type 2 Diabetes – Pipeline by enGene, Inc, H2 2016 211

Type 2 Diabetes – Pipeline by Enzo Biochem, Inc., H2 2016 212

Type 2 Diabetes – Pipeline by Epichem Pty Ltd, H2 2016 213

Type 2 Diabetes – Pipeline by Esperion Therapeutics, Inc., H2 2016 214

Type 2 Diabetes – Pipeline by Eternygen GmbH, H2 2016 215

Type 2 Diabetes – Pipeline by Evotec AG, H2 2016 216

Type 2 Diabetes – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 217

Type 2 Diabetes – Pipeline by FibroStatin SL, H2 2016 218

Type 2 Diabetes – Pipeline by Flamel Technologies S.A., H2 2016 219

Type 2 Diabetes – Pipeline by Generex Biotechnology Corporation, H2 2016 220

Type 2 Diabetes – Pipeline by Genfit SA, H2 2016 221

Type 2 Diabetes – Pipeline by Genovate Biotechnology Co., LTD., H2 2016 222

Type 2 Diabetes – Pipeline by Gero Corp, H2 2016 223

Type 2 Diabetes – Pipeline by Geropharm, H2 2016 224

Type 2 Diabetes – Pipeline by Gilead Sciences, Inc., H2 2016 225

Type 2 Diabetes – Pipeline by GlaxoSmithKline Plc, H2 2016 226

Type 2 Diabetes – Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016 227

Type 2 Diabetes – Pipeline by Glucox Biotech AB, H2 2016 228

Type 2 Diabetes – Pipeline by GW Pharmaceuticals Plc, H2 2016 229

Type 2 Diabetes – Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 230

Type 2 Diabetes – Pipeline by HanAll Biopharma Co., Ltd., H2 2016 231

Type 2 Diabetes – Pipeline by Handok Inc., H2 2016 232

Type 2 Diabetes – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 233

Type 2 Diabetes – Pipeline by HEC Pharm Co., Ltd., H2 2016 234

Type 2 Diabetes – Pipeline by Heptares Therapeutics Limited, H2 2016 235

Type 2 Diabetes – Pipeline by HitGen LTD, H2 2016 236

Type 2 Diabetes – Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 237

Type 2 Diabetes – Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 238

Type 2 Diabetes – Pipeline by Immuron Limited, H2 2016 239

Type 2 Diabetes – Pipeline by Innopharmax Inc., H2 2016 240

Type 2 Diabetes – Pipeline by Innovative Targeting Solutions Inc, H2 2016 241

Type 2 Diabetes – Pipeline by Intarcia Therapeutics, Inc., H2 2016 242

Type 2 Diabetes – Pipeline by Intas Pharmaceuticals Ltd., H2 2016 243

Type 2 Diabetes – Pipeline by Integral Molecular, Inc., H2 2016 244

Type 2 Diabetes – Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 245

Type 2 Diabetes – Pipeline by Intrexon Corporation, H2 2016 246

Type 2 Diabetes – Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 247

Type 2 Diabetes – Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 248

Type 2 Diabetes – Pipeline by Islet Sciences, Inc., H2 2016 249

Type 2 Diabetes – Pipeline by Ixchel Pharma, LLC, H2 2016 250

Type 2 Diabetes – Pipeline by Japan Tobacco Inc., H2 2016 251

Type 2 Diabetes – Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 252

Type 2 Diabetes – Pipeline by Jenrin Discovery, Inc., H2 2016 253

Type 2 Diabetes – Pipeline by JHL Biotech, Inc., H2 2016 254

Type 2 Diabetes – Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2016 255

Type 2 Diabetes – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 256

Type 2 Diabetes – Pipeline by Johnson & Johnson, H2 2016 257

Type 2 Diabetes – Pipeline by Kadimastem Ltd., H2 2016 258

Type 2 Diabetes – Pipeline by Kadmon Corporation, LLC, H2 2016 259

Type 2 Diabetes – Pipeline by Kareus Therapeutics, SA, H2 2016 260

Type 2 Diabetes – Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 261

Type 2 Diabetes – Pipeline by Lead Discovery Center GmbH, H2 2016 262

Type 2 Diabetes – Pipeline by Leading BioSciences, Inc., H2 2016 263

Type 2 Diabetes – Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 264

Type 2 Diabetes – Pipeline by LG Life Science LTD., H2 2016 265

Type 2 Diabetes – Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 266

Type 2 Diabetes – Pipeline by LipimetiX Development Inc, H2 2016 267

Type 2 Diabetes – Pipeline by Lonestar Heart, Inc., H2 2016 268

Type 2 Diabetes – Pipeline by Longevity Biotech, Inc, H2 2016 269

Type 2 Diabetes – Pipeline by Magnus Life Ltd, H2 2016 270

Type 2 Diabetes – Pipeline by Medesis Pharma S.A., H2 2016 271

Type 2 Diabetes – Pipeline by Medestea Research & Production S.p.A., H2 2016 272

Type 2 Diabetes – Pipeline by MedImmune LLC, H2 2016 273

Type 2 Diabetes – Pipeline by Mellitech SAS, H2 2016 274

Type 2 Diabetes – Pipeline by Merck & Co., Inc., H2 2016 275

Type 2 Diabetes – Pipeline by Mesoblast Limited, H2 2016 276

Type 2 Diabetes – Pipeline by Metabolic Solutions Development Company, LLC, H2 2016 277

Type 2 Diabetes – Pipeline by Metabolys SAS, H2 2016 278

Type 2 Diabetes – Pipeline by Metacrine, Inc., H2 2016 279

Type 2 Diabetes – Pipeline by MicroBiome Therapeutics LLC, H2 2016 280

Type 2 Diabetes – Pipeline by MidaSol Therapeutics LP, H2 2016 281

Type 2 Diabetes – Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 282

Type 2 Diabetes – Pipeline by Moderna Therapeutics Inc, H2 2016 283

Type 2 Diabetes – Pipeline by Naia Limited, H2 2016 284

Type 2 Diabetes – Pipeline by Neurimmune Holding AG, H2 2016 285

Type 2 Diabetes – Pipeline by Neurocrine Biosciences, Inc., H2 2016 286

Type 2 Diabetes – Pipeline by NGM Biopharmaceuticals, Inc., H2 2016 287

Type 2 Diabetes – Pipeline by Nordic Bioscience A/S, H2 2016 288

Type 2 Diabetes – Pipeline by Novapeutics, LLC, H2 2016 289

Type 2 Diabetes – Pipeline by Novartis AG, H2 2016 290

Type 2 Diabetes – Pipeline by NovaTarg Therapeutics, Inc, H2 2016 291

Type 2 Diabetes – Pipeline by Novo Nordisk A/S, H2 2016 292

Type 2 Diabetes – Pipeline by Noxxon Pharma AG, H2 2016 293

Type 2 Diabetes – Pipeline by Ogeda SA, H2 2016 294

Type 2 Diabetes – Pipeline by Omeros Corporation, H2 2016 295

Type 2 Diabetes – Pipeline by OPKO Biologics Ltd, H2 2016 296

Type 2 Diabetes – Pipeline by OPKO Health, Inc., H2 2016 297

Type 2 Diabetes – Pipeline by Oramed Pharmaceuticals, Inc., H2 2016 298

Type 2 Diabetes – Pipeline by Orbis Biosciences Inc, H2 2016 299

Type 2 Diabetes – Pipeline by Panacea Biotec Limited, H2 2016 300

Type 2 Diabetes – Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 301

Type 2 Diabetes – Pipeline by Peptron, Inc., H2 2016 302

Type 2 Diabetes – Pipeline by Pfizer Inc., H2 2016 303

Type 2 Diabetes – Pipeline by PharmaCyte Biotech, Inc., H2 2016 304

Type 2 Diabetes – Pipeline by PharmaIN Corporation, H2 2016 305

Type 2 Diabetes – Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 306

Type 2 Diabetes – Pipeline by Pila Pharma AB, H2 2016 307

Type 2 Diabetes – Pipeline by Pivot Pharmaceuticals Inc, H2 2016 308

Type 2 Diabetes – Pipeline by Poxel SA, H2 2016 309

Type 2 Diabetes – Pipeline by Prometheon Pharma, LLC, H2 2016 310

Type 2 Diabetes – Pipeline by ProMetic Life Sciences Inc., H2 2016 311

Type 2 Diabetes – Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016 312

Type 2 Diabetes – Pipeline by Reata Pharmaceuticals, Inc., H2 2016 313

Type 2 Diabetes – Pipeline by ReCyte Therapeutics, Inc., H2 2016 314

Type 2 Diabetes – Pipeline by Red Glead Discovery AB, H2 2016 315

Type 2 Diabetes – Pipeline by RegenMedTX, LLC, H2 2016 316

Type 2 Diabetes – Pipeline by reMYND NV, H2 2016 317

Type 2 Diabetes – Pipeline by Renova Therapeutics Inc, H2 2016 318

Type 2 Diabetes – Pipeline by Saniona AB, H2 2016 319

Type 2 Diabetes – Pipeline by Sanofi, H2 2016 320

Type 2 Diabetes – Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 321

Type 2 Diabetes – Pipeline by SATT Conectus Alsace SAS, H2 2016 322

Type 2 Diabetes – Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 323

Type 2 Diabetes – Pipeline by Selvita S.A., H2 2016 324

List of Figures

List of Figures

Number of Products under Development for Type 2 Diabetes, H2 2016 75

Number of Products under Development for Type 2 Diabetes – Comparative Analysis, H2 2016 76

Number of Products under Development by Companies, H2 2016 77

Number of Products under Investigation by Universities/Institutes, H2 2016 97

Comparative Analysis by Late Stage Development, H2 2016 101

Comparative Analysis by Clinical Stage Development, H2 2016 102

Comparative Analysis by Early Stage Products, H2 2016 103

Assessment by Monotherapy Products, H2 2016 374

Assessment by Combination Products, H2 2016 375

Number of Products by Top 10 Targets, H2 2016 376

Number of Products by Stage and Top 10 Targets, H2 2016 376

Number of Products by Top 10 Mechanism of Actions, H2 2016 398

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 398

Number of Products by Top 10 Routes of Administration, H2 2016 425

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 425

Number of Products by Top 10 Molecule Types, H2 2016 427

Number of Products by Stage and Top 10 Molecule Types, H2 2016 427

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports